Meningococcal Vaccines Market, By Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, Other), By Sales Channel (Public and Private), By Age Group (Infants and Children and Adults), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI3864

Pages :176

Formats :

Excel and PDF

Industry : Biotechnology

Key Developments

In April 2024, GSK plc, a biopharma company, announced that the U.S. FDA had accepted for review a Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY vaccine candidate. This vaccine combines components from GSK's Bexsero and Menveo vaccines, targeting meningococcal groups A, B, C, W, and Y, which are responsible for most cases of invasive meningococcal disease worldwide. The FDA's decision on the application is expected by February 14, 2025.
In October 2023, Pfizer, a multinational pharmaceutical and biotechnology corporation, announced the the U.S. FDA had approved PENBRAYA. It is the first pentavalent vaccine for adolescents and young adults (ages 10-25) to protect against meningococcal groups A, B, C, W, and Y. It combines components from Trumenba and Nimenrix to cover the most common serogroups causing meningococcal disease globally.
In October 2023, WHO pre-qualified a new meningococcal conjugate vaccine, Men5CV, developed by the Serum Institute of India, a biopharmaceuticals company, and PATH. It aims to be affordable and accessible for countries in Africa's meningitis belt, offering protection against deadly meningitis strains. WHO urges its widespread adoption to combat meningitis epidemics by 2030.